牛牛AI助理已提取核心訊息
On August 20, 2024, SeaStar Medical Holding Corporation entered into an At The Market Offering Agreement with H.C. Wainwright & Co., LLC, to sell shares of its common stock through an 'at the market' offering program. The sales will be made on the Nasdaq Capital Market or other trading markets for the company's stock. SeaStar Medical will pay a 3.0% commission on gross sales to Wainwright and provide indemnification and expense reimbursement. The agreement includes customary representations, warranties, and conditions, and the company has the discretion to suspend offers or not sell any shares. The offering will continue until either party terminates the agreement. The shares will be issued under the company's shelf registration statement and related prospectus supplements. A prospectus supplement covering the sale of shares worth $25 million was filed with the SEC on the same date. The ATM Agreement is detailed in Exhibit 10.1 of the current report filed with the SEC, and legal opinions from Dorsey & Whitney LLP regarding the share issuance are included as Exhibit 5.1.
On August 20, 2024, SeaStar Medical Holding Corporation entered into an At The Market Offering Agreement with H.C. Wainwright & Co., LLC, to sell shares of its common stock through an 'at the market' offering program. The sales will be made on the Nasdaq Capital Market or other trading markets for the company's stock. SeaStar Medical will pay a 3.0% commission on gross sales to Wainwright and provide indemnification and expense reimbursement. The agreement includes customary representations, warranties, and conditions, and the company has the discretion to suspend offers or not sell any shares. The offering will continue until either party terminates the agreement. The shares will be issued under the company's shelf registration statement and related prospectus supplements. A prospectus supplement covering the sale of shares worth $25 million was filed with the SEC on the same date. The ATM Agreement is detailed in Exhibit 10.1 of the current report filed with the SEC, and legal opinions from Dorsey & Whitney LLP regarding the share issuance are included as Exhibit 5.1.
2024年8月20日，SeaStar Medical Holding Corporation與H.C. Wainwright & Co. LLC簽訂了一份就通過「市場行動」出售其普通股的協議。銷售將在納斯達克資本市場或公司股票的其他交易市場進行。SeaStar Medical將爲Wainwright支付總銷售額的3.0%作爲佣金，並提供賠償和費用報銷。協議包括常規的陳述、保證和條件，公司有權選擇暫停報價或不銷售任何股票。該交易將持續直到任何一方終止協議爲止。這些股票將根據公司的註冊聲明和相關補充說明書發行。一份覆蓋總共2500萬美元股票銷售的補充說明書於同一日期向SEC提交。關於股票發行的法律意見書來自Dorsey & Whitney LLP，包括在提交給SEC的當前報告的10.1展示中。
2024年8月20日，SeaStar Medical Holding Corporation與H.C. Wainwright & Co. LLC簽訂了一份就通過「市場行動」出售其普通股的協議。銷售將在納斯達克資本市場或公司股票的其他交易市場進行。SeaStar Medical將爲Wainwright支付總銷售額的3.0%作爲佣金，並提供賠償和費用報銷。協議包括常規的陳述、保證和條件，公司有權選擇暫停報價或不銷售任何股票。該交易將持續直到任何一方終止協議爲止。這些股票將根據公司的註冊聲明和相關補充說明書發行。一份覆蓋總共2500萬美元股票銷售的補充說明書於同一日期向SEC提交。關於股票發行的法律意見書來自Dorsey & Whitney LLP，包括在提交給SEC的當前報告的10.1展示中。
有用
沒用
譯文內容由第三人軟體翻譯。
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
風險及免責聲明
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了
風險及免責聲明
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了